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1. Introduction 
Gene expression profiling has been used extensively in multiple fields of research to 
compare disease and control samples, to investigate mechanisms of disease, to identify 
subtypes within a heterogeneous clinical phenotype and to establish responses to a specific 
treatment. In addition, it can also be used to determine the function of a gene, to monitor 
changes over time, or for discovering cell specific expression or responses.  
This chapter will initially explain the principles of gene expression profiling, before 
discussing the sources of samples, along with their advantages and limitations, and will 
then summarise the research to date regarding the application of gene expression profiling 
to amyotrophic lateral sclerosis (ALS). 
2. What is gene expression profiling? 
The primary application of gene expression profiling is to use a glass slide containing 
oligonucleotides or cDNA sequences, termed a microarray, to quantify the amount of 
individual RNA transcripts that are present in a particular cell or tissue.  RNA is extracted, 
fluorescently labelled and then hybridized to the microarray.  A linear amplification step 
can also be performed prior to labelling to ensure sufficient RNA is generated from low 
yields of RNA extracted from small sample sizes.  The quantity of labelled RNA binding to 
each oligonucleotide or cDNA sequence on the microarray determines the intensity of 
fluorescence at that location and thus allows quantification of the RNA transcripts in the 
initial sample (Stoughton 2005).   
Comparison of the expression of transcripts between sample groups allows identification of 
transcripts which are differentially expressed between the groups.  The large number of 
genes simultaneously interrogated by a microarray means that the resulting data are 
amenable to study the expression of inter-related clusters of genes such as those involved in 
known functional categories or specific pathways. Changes in expression level of a 
particular gene do not take into account regulation at the level of translation. However, the 
functional impact of a differentially expressed gene can be subsequently established by 
assaying the encoded protein expression or function.   
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The advent of next generation sequencing, and specifically the sequencing of all RNA 
molecules in a quantitative manner, has recently become an alternative, though expensive 
method for measuring levels of gene expression. However, this has the potential to add 
further knowledge and value to the application of gene expression profiling to disease.  
3. Uses of gene expression profiling 
Quantification of the transcriptome has been a useful mechanism for both discovering and 
defining mechanisms of pathogenesis in ALS (Cox et al 2010; Ferraiuolo et al 2007; Kirby et 
al 2005; Kirby et al 2011).  In particular lists of differentially expressed genes can be usefully 
converted to functional ‘themes’ by an enrichment analysis (Hosack et al 2003).  Various 
categorisations exist, including the gene ontology (GO) and Kyoto encyclopaedia of genes 
and genomes (KEGG), which classify genes according to molecular function, biological 
process, cellular component or a known biological pathway.   
A frequent application of gene expression profiling has been the development of putative 
biomarkers via a supervised classification approach (Booij et al 2011; Nagasaka et al 2005; 
Scherzer et al 2007).  The large number of targets quantified simultaneously by gene 
expression profiling is essential for biomarker discovery, as it allows an unbiased survey of 
the most informative RNA transcripts. A reliable biomarker(s) for defining pathogenesis 
and prognosis in ALS has yet to be established, though gene expression profiling is one of 
the methodologies currently being used to establish an ALS biomarker(s). 
4. Sources of material for studying ALS 
In ALS, the vulnerable cells are the motor neurones, located in the motor cortex, brainstem 
and spinal cord. Since motor neurones cannot be sampled during life, model systems, such 
as neuronal-like cells in culture and animals carrying mutant transgenes, have been used to 
study the neurodegenerative process. In addition to sampling post-mortem material from 
patients, peripheral tissue from living patients (and neurologically normal controls) has 
been used as a source material for applying gene expression profiling to ALS.   
4.1 Cellular models of ALS 
Neuronal cell lines, both human (e.g. SH-SY5Y) and rodent (e.g. PC12), have been used as a 
model to investigate mechanisms of neurodegeneration. However, one of the most widely 
used cellular models for examining the molecular pathophysiology underpinning the 
neurodegenerative disease process in ALS is the mouse spinal cord/neuroblastoma cell line 
NSC-34 (Cashman et al 1992). Immortalized NSC-34 cells recapitulate many of the 
characteristics of motor neurones whilst maintaining their ability to proliferate in culture; 
thus providing a continual resource of motor neurone-like cells (Cashman et al 1992; 
Durham et al 1993). In particular, they have proved a robust model of mutant copper zinc 
superoxide dismutase-1 (SOD1) associated familial ALS (FALS), as they can be transfected 
with vectors carrying normal or mutant forms of the human SOD1 gene (Durham et al 1997; 
Menzies et al 2002a; Menzies et al 2002b). Cellular models of TDP-43-related ALS, caused by 
mutation of the TAR DNA binding protein gene (TARDBP) are being generated (Duan et al 
2010; Igaz et al 2009), though sustained over-expression of the wild-type and mutant 
proteins is proving problematic due to the toxicity of both the wild-type and mutant over-
expressed proteins and the tight auto-regulation of TDP-43 (Budini & Buratti 2011). 
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Gene expression profiling of cell lines transfected with ALS associated genes provides a 
genetically homogenous cell population uncontaminated by non-neuronal astrocytes and 
other types of glial cells, which are present in the central nervous system (CNS). 
Furthermore, environmental conditions can easily be manipulated and tightly controlled in 
vitro so as to reduce the impact of external confounding factors on gene expression. The 
limitations of this type of model system include the fact that NSC-34 cell lines (or other 
neuronal cell lines) are continually dividing cells, rather than post-mitotic cells and they are 
unable to mirror the effects of cellular interactions that occur between the different cell 
populations in situ (Kirby et al 2011). 
Primary neuronal and astrocytic cells can be isolated from embryonic mice and short-term 
cultures generated for microarray analysis. These cells more closely mirror those present in the 
CNS, though the primary neuronal cultures, as they are post-mitotic cells, have a limited 
lifespan of 7-10 days. In contrast, cultured primary astrocytes are able to proliferate in culture. 
Whilst co-cultures or separated co-cultures allow a degree of interaction between the two cell 
types, these types of mixed cultures have not yet been used for microarray analysis in ALS. 
4.2 Animal models of ALS 
Transgenic mice expressing mutant forms of ALS-related genes provide a source of RNA for 
microarray analysis. For investigating the mechanisms of SOD1-related neurodegeneration, 
mice over-expressing the human p.G93A or mouse p.G86R mutant forms of the SOD1 protein 
(SOD1G93A or SOD1G86R) have been used as they develop an age dependent neuromuscular 
condition; the motor function symptoms and histopathological features have been extensively 
characterised and resemble those observed in both SOD1-related ALS and classical ALS 
patients (Gurney et al 1994; Ripps et al 1995). In contrast, over-expression of wild-type human 
SOD1 (SOD1WT) does not produce an overt motor phenotype, supporting a toxic gain of 
function by the mutant SOD1 protein as the mechanism by which the mutant proteins cause 
cell death. In contrast, mouse models over-expressing either wild-type or mutant TDP-43 show 
a neurodegenerative phenotype (Igaz et al 2011; Stallings et al 2010). 
One of the major advantages of using animal models for microarray analysis is the ability to 
examine animals at different ages in order to investigate the progression of disease, an 
approach that is unattainable in human post-mortem tissue. Valuable insights regarding 
onset of disease can be established in pre-symptomatic and early symptomatic disease 
stages since these represent time points at which the identification of key novel targets for 
therapeutic intervention could be best placed to rescue vulnerable neuronal cell populations 
before the development of irreversible neuronal injury (Ferraiuolo et al 2007). In addition, 
sampling of specific cell types from the CNS allow gene expression changes to be identified 
which include the effects of interactions with neighbouring cells.  
Backcrossing of the SOD1WT and SOD1G93A mice with C57Bl6 mice has led to the formation 
of SOD1WT and SOD1G93A mice on a homogeneous background (Ferraiuolo et al 2007). The 
use of these mice for microarray analysis and the use of non-transgenic littermates as 
controls have proven effective in reducing inter-individual genetic variability to ensure the 
generation of consistent and reliable gene expression data.  
4.3 Human post-mortem material 
Human post-mortem brain and spinal cord specimens derived from clinically and 
pathologically confirmed cases of ALS can be used in comparisons with age, gender and 
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ethnically matched neurologically normal controls and are a pivotal source of RNA for gene 
expression profiling in ALS. Brain and spinal cord represent the tissues that are most 
susceptible to the underlying neurodegenerative disease process. However, there are a 
number of limitations that should be taken into account when using this tissue. First and 
foremost, the transcriptional changes that are detected are reflecting the terminal stage of 
disease, with the majority of vulnerable neuronal cells having already undergone cell death 
(Sharp et al 2006). Therefore, it can be difficult to distinguish whether the changes detected 
are due to the survival response in the remaining cells, initiation of a cell death pathway (if 
the cells are beginning to die), or whether the changes are present in response to a 
pathogenic trigger (Lederer et al 2007). Secondly, samples, and particularly control material, 
are difficult to obtain and often in short supply. This restricts the sample sizes that can be 
used, which has a negative impact upon the statistical power of such studies. Considerable 
heterogeneity exists between individuals in disease and control groups and gene expression 
changes may also be influenced by post-mortem interval, variability in brain pH, degree of 
neuroinflammation and sample type including white versus grey matter or cortical motor 
neurones versus spinal motor neurones. Furthermore, ex vivo RNA degradation, particularly 
during sample preparation, should also be taken into consideration (Maes et al 2007).  
RNA extraction protocols are faster and more straightforward for whole tissue 
homogenates. However, the inclusion of a heterogeneous mixture of cell populations may in 
effect blur the distinctive profile emanating from the neuronal cells that are most affected in 
ALS (Kirby et al 2011). In comparing the gene expression profiles generated from diseased 
tissue to that of healthy controls there is also the added issue of a shift in the proportion of 
different cell populations within the sample as neurodegeneration is characterised by the 
loss of motor neurones and the active proliferation of non-neuronal microglia and 
macrophages (Dangond et al 2004). Laser capture microdissection (LCM) may be a more 
expensive and laborious technique but is beneficial in studying a neuronal enriched cell 
population (Jiang et al 2005). It also is noteworthy that in comparison to primary cultures 
these cells have had the benefit of being embedded within their natural environment where 
physiologically relevant cross talk has taken place with neighbouring cells and tissues 
(Ferraiuolo et al 2007). 
4.4 Human peripheral tissue samples 
Peripheral tissue such as whole venous blood, cultured skin fibroblasts and muscle biopsy 
material offer an attractive and readily accessible resource for microarray analysis in ALS. 
Samples can be collected longitudinally, particularly as the collection of blood is relatively 
non-invasive and sampling techniques can be standardized across research centres (Highley 
et al 2011; Saris et al 2009; Shtilbans et al 2011; Tsuang et al 2005).  
Blood is classified as a fluid connective tissue composed of plasma (55%), erythrocytes 
(43%), leukocytes (0.5%) and platelets (1.5%) which continuously permeates and interacts 
with every other tissue and organ of the mammalian body. It is in a permanent state of 
renewal and is known to play a pivotal role in physiological homeostasis, cellular immunity 
and inflammation (Mohr & Liew 2007). Since 80% of the genes routinely expressed within 
the CNS have also been detectable in circulating blood cells it is anticipated that there are 
quantifiable changes in the levels of these gene transcripts which have the potential to act as 
a sentinel of disease (Liew et al 2006). Evidence suggests that the shear abundance of 
endogenous alpha and beta globin messenger RNA (mRNA), which constitutes up to 70% of 
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erythrocytic mRNA transcripts, masks the expression of less abundant genes of potential 
biological significance as a result of their high signal intensity on the microarray (Wright et 
al 2008). Thus, strategies have been developed and evaluated to remove these transcripts 
present in the RNA samples from whole blood (Liu et al 2006). Alternatively, fractionation 
of peripheral blood mononuclear cells (PBMCs) can also be used though the additional 
processing steps involved in isolating the PBMCs can introduce spurious artifactual 
alterations in gene expression that are not attributable to the disease (Whitney et al 2003). 
Fibroblasts are not known to have any direct involvement in ALS, though they provide a 
model with the genetic background of the individual and have the added value of being a 
source for the generation of induced pluripotent stem cells (iPS) or for the direct 
manipulation into motor neuronal cells (Dimos et al 2008; Son et al 2011). In addition, 
fibroblasts have been shown to reflect changes in patients with neurodegenerative disease 
(Aguirre et al 1998; Hoepken et al 2008; Mortiboys et al 2008) and their gene expression 
profiles distinguish pre-symptomatic individuals from those of controls (Nagasaka et al 
2005). In contrast to fibroblasts, skeletal muscle is severely affected by the disease. Whilst 
muscle biopsies are the most invasive sample to collect, they are a useful source for gene 
expression profiling, as they provide a window into the mechanisms involved in the 
neuromuscular degeneration that occur in ALS during life (Dadon-Nachum et al 2011; 
Dupuis & Loeffler 2009).  
5. Results from use of cellular models of ALS 
Gene expression profiling of the widely used NSC34 cellular model of SOD1-related FALS 
identified a marked degree of transcriptional repression in the presence of the SOD1G93A 
mutation (Kirby et al 2005). These repressed genes included a group of antioxidant response 
(ARE) genes or “programmed cell life” genes that are regulated by the Nrf2 transcription 
factor (Figure 1). Reduced expression of Nrf2 and selected downstream targets was seen at 
both the RNA and protein levels in the cellular model and NRF2 dysregulation was also 
demonstrated in isolated motor neurones from SOD1-related ALS cases. Subsequent work 
by Sarlette and colleagues has shown that NRF2 transcription and translation is also 
decreased in SALS cases (Sarlette et al 2008). Most recently, it has been demonstrated that 
activation of Nrf2 in NSC34 SOD1-related ALS cell models, primary motor neurone and 
astrocyte co-cultures and in the SOD1G93A mouse model all improve neuronal survival 
(Neymotin et al 2011; Vargas et al 2008a). 
Primary astrocyte cultures prepared from mutant SOD1 rodent models have been shown to 
increase motor neuronal death in co-cultures (Nagai et al 2007; Vargas et al 2006). To 
investigate this effect, gene expression profiling was performed on RNA isolated from 
astrocyte cultures generated from SOD1G93A rats (and litter mate controls). Perhaps 
surprisingly, there were limited differences in the transcriptional profiles of transgenic and 
non-transgenic astrocytes (Vargas et al 2008b). However, of the two genes most dysregulated, 
regulator of differentiation (Rod1) and decorin (Dcn), both showed consistent changes in 
asymptomatic and early symptomatic rats, implicating components of RNA processing and 
the extracellular matrix as contributors early in the disease process (Figure 1). 
Primary neuronal cultures originating from SOD1G93A mice and subjected to oxidative stress 
(H2O2) or excitotoxicity (NMDA), demonstrated a greater level of cell death, compared to 
non-transgenic cultures (Boutahar et al 2011). Microarray analysis detected cytoskeletal 
remodelling and vesicular transport related genes as increased in response to oxidative 
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stress, whilst genes involved in the ubiquitin-proteasome system and cytokines were 
increased following excitotoxicity (Figure 1). Several of these pathways have already been 
implicated as playing a pathogenic role in ALS and add further support to the idea that the 
proposed disease mechanisms are mutually compatible. 
 
 
Fig. 1. Summary of prominent pathways arising from GEP of Cellular Models. Important 
changes in the transcriptome have been highlighted by green labels; yellow stars indicate 
up-regulation, red stars indicate down-regulation. Blue squares outline functional 
consequences of changes in the transcriptome. Further details are discussed in the text.  
6. Results from use of animal models of ALS 
6.1 Gene expression profiling of mixed cell type CNS samples 
Microarray analysis of whole spinal cord homogenates from ALS mouse models have been 
performed by several research groups in order to obtain a global view of changes in the CNS 
prior to and during disease. Results from SOD1G93A mice have shown that inflammation, 
apoptosis and adaptive responses to metal ion dysregulation are the main pathways 
activated in both pre-symptomatic mice and during the disease process (Olsen et al 2001; 
Yoshihara et al 2002) (Figure 2). Analysis of the SOD1L126delTT transgenic mouse, which 
results in a truncated SOD1 protein, also showed pre-symptomatic changes related to the 
reactive gliosis which is occurring in the spinal cord (Fukada et al 2007).  
Recently, transgenic mice carrying mutant TDP-43 have also contributed to better 
understanding the different mechanisms involved in ALS. Transgenic mice induced to 
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express human TDP-43 without the nuclear localization signal (hTDP43-delNLS) developed 
signs of motor spasticity, neurone loss in forebrain regions and corticospinal tract 
degeneration (Igaz et al 2011). Microarray analysis of hTDP43-delNLS expression in the 
cortex of mutant mice, following 2 weeks induction of the mutant protein, detected dramatic 
changes in gene expression, with the most enriched pathway being chromatin assembly 
(Figure 2).  Interestingly, after only 2 weeks of hTDP43-delNLS induction, markers of 
inflammation and neuronal loss were unchanged. 
 
 
Fig. 2. Summary of prominent pathways arising from GEP of Animal Models. Important 
changes in the transcriptome have been highlighted by green labels; yellow stars indicate 
up-regulation, red stars indicate down-regulation.  Blue squares outline functional 
consequences of changes in the transcriptome.  Further details are discussed in the text.  
Although these studies have greatly contributed to present knowledge on the transcriptional 
changes occurring in ALS, the analysis of a mixed cell population within the CNS has several 
disadvantages. This kind of approach does not identify which cell population is responsible 
for the transcriptional changes observed and only detects those transcripts most highly 
differentially expressed, with subtle but potential pivotal gene expression changes masked as 
well as changes in genes differentially expressed in one cell type, but not in others.  
6.2 Gene expression profiling of laser capture microdissection isolated cell types 
In order to overcome the limitations of using mixed cell population samples, dissection of 
single cells from complex tissues using LCM has been applied to identify the contribution of 
different cell types to the degenerative process occurring in ALS. 
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Several studies have determined the changes in gene expression occurring in motor 
neurones isolated from the spinal cord of mutant SOD1G93A mice at different stages during 
the disease; from the pre-symptomatic stage to paralysis (Ferraiuolo et al 2007; Perrin et al 
2005). The first report described transcriptional analysis of motor neurones isolated from 
SOD1G93A mice bred on a mixed background and no differentially expressed genes were 
detected in the pre-symptomatic mice (Perrin et al 2005). However, in contrast to the whole 
tissue homogenates, motor neurones did not show activation of apoptotic genes, suggesting 
that cell death signals derive from other cell types in the spinal cord (Figure 2).  
In the second publication, microarray analysis was carried out on SOD1G93A mice bred on a 
homogeneous background; this enabled important changes in the motor neurones at the 
pre-symptomatic stage of disease, mainly involved in carbohydrate metabolism and 
transcription, to be detected (Ferraiuolo et al 2007). The upregulation of transcripts encoding 
proteins involved in the energy production pathway, i.e. tricarboxylic acid cycle and 
respiratory chain, suggested that motor neurones were trying to compensate for their 
increased energy needs in response to ongoing stress. At the late stage of disease, increased 
expression of transcripts involved in reactivation of the cell cycle (as an alternative pathway 
of cell death), and complement activation (a mechanism through which motor neurones can 
attract cells from the immune system), and down-regulation of transcription-related genes 
were identified (Figure 2).  
To complement the gene expression profiling of motor neurones, astrocytes isolated from 
SOD1G93A mice at the pre-symptomatic stage of disease were isolated and used for 
microarray analysis (Ferraiuolo et al 2011a). This enabled the cross-talk between the motor 
neurones and astrocytes at this very early time point to be interrogated. Interestingly, 
astrocytes displayed a marked impairment of carbohydrate metabolism (Figure 2). 
Comparing the expression profiles of the two cell types from the same SOD1G93A mice 
highlighted that the metabolic impairment observed in motor neurones could derive from 
the lack of provision of substrates, i.e. lactate, from the astrocytes, and led to the conclusion 
that the lactate shuttle (the mechanism through which motor neurones and astrocytes 
combine metabolism and signalling through lactate and glutamate), is impaired. In addition, 
the activation of an important neuronal cell death pathway involving p75 and its ligand pro 
nerve growth factor (proNGF) was established. Gene expression profiling of SOD1G93A 
astrocytes demonstrated that these cells expressed high levels of Ngf, while the motor 
neurones over-expressed the p75 receptor. In vitro data confirmed the dysregulation of both 
pathways and preliminary data from human ALS biosamples supported these findings from 
the murine model.   
6.3 Gene expression profiling of peripheral tissue from mouse models 
Microarray technology has also been applied to peripheral tissues from the SOD1G86R mouse 
model (Gonzalez de Aguilar et al 2008). Profiling of the skeletal muscles revealed that the 
major expression changes happen at onset of disease, when muscles are activating pathways 
involved in detoxification and regeneration, but also cell death and tissue degradation. 
These findings revealed that while motor neurones are degenerating, muscles are 
undergoing major remodelling trying to compensate for muscle damage with new 
myogenesis. Whilst over-expression of transcripts such as cyclin-dependent kinase 
inhibitor-1A (Cdkn1a) and growth arrest-and DNA damage-inducible gene-45 (Gadd45) 
could be mediating apoptosis of myofibres resulting in muscle atrophy, increased 
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expression B cell translocation gene-1 (Btg1), growth differentiation factor-5 (Gdf5) and 
myogenic factor-6 (Myf6) are potent activators of new fibre formation.  
7. Results from use of human post-mortem material 
7.1 Gene expression profiling of mixed cell type CNS samples 
Multiple studies have utilised gene expression profiling of post mortem mixed cell samples 
from ALS patients and controls;  these have either focused on using samples from the motor 
cortex (Lederer et al 2007; Wang et al 2006) or from the spinal cord (Dangond et al 2004; 
Malaspina et al 2001; Offen et al 2009). The majority used sporadic ALS (SALS) cases, 
though Dangond et al also sampled two FALS cases, one of which carried an SOD1 
mutation (Dangond et al 2004).  Despite the different tissues profiled and the different 
platforms utilised, the studies showed some consistent results: All of the studies recorded 
altered gene expression related to inflammation and Malaspina and colleagues detected an 
increase in glial fibrillary acidic protein (GFAP), indicating active astrogliosis (Figure 3). In 
addition, a number of the studies discovered differential expression related to cytoskeleton 
function, protein processing and the antioxidant response, in agreement with other lines of 
research in ALS (Ferraiuolo et al 2011b).  
 
 
Fig. 3. Summary of prominent pathways arising from GEP of Human Tissue. Important 
changes in the transcriptome have been highlighted by green labels; yellow stars indicate 
up-regulation, red stars indicate down-regulation.  Blue squares outline functional 
consequences of changes in the transcriptome. Further details can be found in the text.  
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7.2 Gene expression profiling of laser capture microdissection isolated cell types 
As with the mouse models, in order to determine those genes differentially expressed in the 
vulnerable cell type, LCM has been used in post-mortem material to isolate the motor 
neurones from the spinal cord.  
Motor neurones isolated from SALS cases and neurologically normal controls were shown 
to have distinct gene expression profiles compared to those generated from ventral horn 
homogenates, particularly with respect to those genes down-regulated in motor neurones 
(Jiang et al 2005). The motor neurones showed differential expression of genes associated 
with the cytoskeleton and evidence of decreased transcription, whilst cell death-associated 
genes and those involved in cell signalling were increased (Figure 3). In addition, cell cycle 
related genes were also reported as dysregulated, supporting the theory that inappropriate 
activation of the cell cycle in these post-mitotic cells leads to cell death. A follow-up study 
demonstrated that expression of several of these genes also correlated with pathological 
markers, such as phosphorylated neurofilament and ubiquitinated protein accumulations as 
well as motor neurone loss (Jiang et al 2007). 
Gene expression profiling of isolated motor neurones has also been performed on ALS cases 
which carry genetic mutations in the SOD1 and chromatin modifying protein 2B (CHMP2B) 
genes (Cox et al 2010; Kirby et al 2011). Motor neurones from SOD1-related cases of ALS 
showed increases in genes in the protein kinase B/phosphatidylinositol-3 kinase 
(AKT/PI3K) cell survival pathway, with concomitant decreases in negative regulators such 
as phophastase and tensin homologue (PTEN) (Kirby et al 2011) (Figure 3). Further work 
demonstrated that inhibition of PTEN led to increased activation of the AKT/PI3K pathway 
and increased neuronal survival in cell models including primary motor neurone cultures. 
Thus, activation of the AKT/PI3K pathway was proposed as a candidate for future 
therapeutic strategies. 
The transcriptional profiles from motor neurones isolated from the CHMP2B-related ALS 
cases were distinct from those in SOD1-related cases (Cox et al 2010). These motor neurones 
showed dysregulation of genes involved in the classical and p38 MAPK signalling 
pathways, gene changes predicted to reflect reduced autophagy and repression of 
translation (Figure 3). The functional implication of CHMP2B mutations on cellular 
mechanisms was demonstrated by the presence of large cytoplasmic vacuoles and 
impairment of autophagy in a cellular model transfected with mutant CHMP2B, consistent 
with the microarray findings (Cox et al 2010). Interestingly, differential expression of genes 
encoding proteins responsible for calcium handling and cell cycle genes, as well as those 
genes involved in transcription, signalling and metabolism, was detected in both genetic 
subtypes. 
8. Results from use of human peripheral tissue 
Gene expression profiling has been conducted on blood and fibroblasts from ALS patients 
(Highley et al 2011; Saris et al 2009; Zhang et al 2011).  Microarray analysis of SALS and 
control blood samples was followed by hierarchical clustering of all genes found to be 
significantly expressed in all samples after normalisation (Saris et al 2009). The method 
identified five clusters; two of which were able to differentiate between ALS and control 
samples.  These clusters were replicated in a further two cohorts of patients and controls, 
demonstrating that such an analysis, which takes into account the interdependence of gene 
expression, is a means of reducing the false negative rate when subsequently detecting 
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differential gene expression. This work also provided evidence that peripheral blood is a 
valuable medium for studying ALS.  In addition, there was a correlation with the CNS tissue 
studies, as the blood in ALS patients showed a decrease in genes associated with protein 
processing and RNA post-transcriptional modification, as well as increases in genes 
associated with inflammation. 
A more recent study performed gene expression profiling on peripheral blood mononuclear 
cells from patients with SALS (Zhang et al 2011).  These cells showed an up-regulation of 
genes associated with immune activation in response to lipopolysaccharide (LPS), which 
correlated with an elevation of plasma LPS. Unfortunately, no correlation between 
expression of these genes and disease progression was provided.     
Transcriptional profiles of fibroblasts from patients with SALS, FALS and controls have 
been shown to be informative in distinguishing the different genetic variants from each 
other, as well as from SALS patients, by their gene expression profiles and specifically the 
level of alternative splicing (Highley et al 2011). The FALS samples were derived from 
patients with mutations in SOD1 and TARDBP. Using microarrays which interrogate every 
exon of every gene, it was demonstrated that there was a significant amount of aberrant 
splicing in the samples with a TARDBP mutation which was replicated to a lesser degree in 
the SALS samples and virtually absent in the samples with a SOD1 mutation (Figure 3).  In 
support of this, other work has identified aberrant splicing in cell and animal models with 
depletion of TDP-43 (Polymenidou et al 2011; Tollervey et al 2011). 
9. The future of gene expression profiling in ALS 
9.1 RNA sequencing (RNA-seq) 
The advent of next generation sequencing has evolved to enable quantitative parallel 
sequencing of RNA transcripts from isolated cells and tissues. There are a number of 
advantages of next generation RNA sequencing over the microarray platform which in 
general extend from the fact that there is no reliance on the pre-designed probes which are 
present on the microarrays.  In contrast, the methodology aims to sequence every base of 
every transcript of RNA.  This leads to a better detection rate of known transcripts and 
splicing events and the detection of RNA transcripts (both coding and non-coding) which 
have not previously been described and therefore have no specific probe (Sultan et al 2008).  
As there is no reliance on probes, the problem of cross hybridisation is avoided.  In addition, 
because each base in each transcript is sequenced, as well as providing information about 
expression level and alternative splicing, the sequencing also provides information about 
sequence variability within the RNA (Wang et al 2009).  The biggest challenge to RNA 
sequencing, however, is the analysis of the large amounts of data produced which is 
substantially more than the read out of even the most comprehensive microarray.  Not least 
among these challenges is the problem of mapping the RNA sequences to the genome, as in 
contrast to DNA sequencing, the absence of introns can lead to substantial difficulties 
(Sutherland et al 2011).   
9.2 Role of microRNAs in ALS 
This chapter has focused on the mRNA that is translated into protein. However, although 
90% of eukaryotic genomic DNA is transcribed, only 1-2% actually encodes protein.  The 
vast majority of transcribed material is comprised of non-coding RNA (ncRNA) and there is 
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increasing evidence to support functional roles for at least a subset of these transcripts 
(Kaikkonen et al 2011). There are broadly two types of ncRNA, infrastructural (including 
transfer RNA and small nuclear RNA) and regulatory RNA (including microRNA, Piwi-
interacting RNA and small interfering RNA).  The function of ncRNAs remains largely 
unknown. However, research into microRNA (miRNA) has led the field in recent years.  
miRNAs are a class of small, ncRNA molecules predicted to post-transcriptionally regulate 
at least one third of human genes (Lewis et al 2005). Each miRNA can potentially target 
hundreds of genes and play key regulatory roles in a diverse range of pathways including 
development, differentiation and pathological processes such as neurodegeneration (Enciu 
et al 2011).  The study of miRNA in ALS is at a very early stage. However, given the 
proposed role for TDP-43 in miRNA biogenesis and the recent discovery of a beneficial 
effect of miRNA-206 in the mutant SOD1 mouse model, this will be an interesting area of 
investigation for the future (Buratti et al 2010; Williams et al 2009) 
9.3 Biomarkers in ALS 
There is no diagnostic test for ALS, so diagnosis currently relies upon clinical assessment 
involving the exclusion of “ALS-mimic” syndromes (such as multifocal motor neuropathy 
and cervical radiculomyelopathy), causing an average delay of one year from symptom 
onset to a confirmed diagnosis (Silani et al 2011; Zoccolella et al 2006). In such a rapidly 
progressive disease this delay is a significant obstacle to potential neuroprotective therapies. 
ALS is clinically heterogeneous, with multiple subtypes associated with different survival 
times and symptoms making prognosis challenging. This heterogeneity is also a 
confounding factor for clinical trials as patient phenotype will impact upon survival data 
and may influence responses to therapeutic intervention, with some subtypes more 
responsive to therapy than others (Turner et al 2009). Robust biomarkers would therefore be 
valuable for the initial diagnosis of disease, the classification of various subtypes, 
monitoring responses to therapeutic agents and tracking disease progression (Turner et al 
2009).  Gene expression profiling offers a useful tool for biomarker discovery allowing 
patient and control biofluids, such as blood and CSF, to be compared on a genome wide 
scale.  These tools have already been employed to improve classification and diagnosis of 
multiple diseases including neurodegenerative conditions such as Huntington’s disease and 
Parkinson’s disease (Borovecki et al 2005; Scherzer et al 2007). 
10. Conclusion 
In conclusion, microarray analysis has been pivotal in understanding the transcriptional 
alterations occurring in response to genetic mutations associated with ALS and the sporadic 
disease (SALS). The cellular model has generated a therapeutic target and transcriptional 
activation of Nrf2 is currently being assessed in-vivo. Use of spinal cord and peripheral 
tissues from transgenic mouse models has provided a mechanism to look at the progression 
of the disease and specifically to identify early changes in the motor neurones and 
astrocytes. These dysregulated pathways provide future therapeutic targets. In addition, 
gene expression profiling has allowed crucial insights into the mechanisms affecting 
different areas of the motor system, with the combination of LCM and microarray 
technology able to discriminate changes in specific cell types and understand how these 
affect each other and contribute to disease progression. Finally, the use of human material 
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has begun to allow the distinctions between genetic and sporadic disease to be differentiated 
as well as providing further candidates for therapeutic approaches. In the future, gene 
expression profiling of larger, consistently collected patient samples has the potential to 
generate robust and reliable prognostic and diagnostic biomarkers, which will ultimately be 
applicable for use in the clinic.  
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